TransMedics Group (NASDAQ:TMDX) Issues Earnings Results, Beats Expectations By $2.21 EPS

TransMedics Group (NASDAQ:TMDX) announced its quarterly earnings results on Tuesday. The company reported $2.62 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $2.21, FiscalAI reports. The company had revenue of $160.76 million during the quarter, compared to analyst estimates of $155.28 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.

TransMedics Group Stock Up 2.3%

NASDAQ:TMDX traded up $3.13 on Tuesday, reaching $137.78. 1,239,486 shares of the stock traded hands, compared to its average volume of 729,200. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. The company has a market capitalization of $4.71 billion, a price-to-earnings ratio of 55.78 and a beta of 2.06. TransMedics Group has a 12 month low of $62.07 and a 12 month high of $156.00. The company’s fifty day simple moving average is $132.73 and its 200 day simple moving average is $126.05.

Insider Buying and Selling

In other TransMedics Group news, Director David Weill sold 5,000 shares of TransMedics Group stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the sale, the director owned 12,134 shares of the company’s stock, valued at approximately $1,682,257.76. This trade represents a 29.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Gerardo Hernandez sold 920 shares of the company’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the transaction, the chief financial officer directly owned 15,064 shares in the company, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Large investors have recently modified their holdings of the company. Pacer Advisors Inc. purchased a new stake in TransMedics Group during the fourth quarter valued at $162,000. Corient Private Wealth LLC grew its stake in shares of TransMedics Group by 32.5% during the 4th quarter. Corient Private Wealth LLC now owns 3,084 shares of the company’s stock valued at $375,000 after purchasing an additional 757 shares during the period. Summit Global Investments increased its position in shares of TransMedics Group by 3.6% during the 4th quarter. Summit Global Investments now owns 3,260 shares of the company’s stock valued at $397,000 after purchasing an additional 112 shares during the last quarter. EP Wealth Advisors LLC bought a new position in shares of TransMedics Group in the 4th quarter worth approximately $210,000. Finally, Regal Partners Ltd bought a new position in shares of TransMedics Group in the 4th quarter worth approximately $1,046,000. Institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Canaccord Genuity Group lifted their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Piper Sandler reissued an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Needham & Company LLC lifted their price target on TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Morgan Stanley increased their price objective on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Finally, Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, February 14th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $144.25.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.